Omnipod 5 Boosts Glycemic Control in MDI Users with T1D: Daily Dose

_{©New Africa/AdobeStock}

Patient Care brings primary care clinicians a lot of medical news every day—it’s easy to miss an important study. The Daily Dose provides a concise summary of one of the website's leading stories you may not have seen.

On March 27, 2025, we reported on the first randomized controlled clinical trial to evaluate direct transition from multiple daily injections (MDI) to automated insulin delivery (AID) in adults and children with type 1 diabetes (T1D) who were not meeting glycemic targets with injections.

The study

The RADIANT trial enrolled 188 participants aged 4 to 70 years with T1D and suboptimal glycemic control (HbA_1c 7.5-11%). Of the group, more than half (58%) were aged 4 to 17 years. All participants had been using MDI with CGM for at least 3 months before the study. The multinational trial was conducted across 19 clinical centers in France, the United Kingdom, and Belgium.

Participants were randomly assigned to either initiate the Omnipod 5 AID System (n = 125) or continue their usual MDI plus CGM therapy (n = 63) for 3 months. The average baseline HbA_1c was 8.1% across both groups.

The findings

After 3 months, participants using Omnipod 5 achieved an average HbA_1c reduction of 0.8% compared to those continuing MDI with continuous glucose monitoring (CGM). For participants with baseline HbA_1c levels above 8.0%, the improvement after transition was even more pronounced at 1.0% compared to the control group.

Most notably, participants in the group using the Omnipod 5 System spent an additional 5.4 hours per day with glucose levels in target range (70 to 180mg/dL) without experiencing increased hypoglycemia. The greater time in range reflected a rise from a baseline of 39% to 65% in the Omnipod 5 group.

Authors' comments

"Omnipod 5 has proved clinical efficacy in people living with type 1 diabetes. The RADIANT experience showed us that it was easy to implement in pump-naïve patients, with very good results. It encourages us to pursue a direct switch from multiple daily injections to automated insulin delivery so patients can immediately receive the clear benefits, without a long period of manual pump treatment."

Click here for more details.